BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holmboe S, Hansen PL, Thisgaard H, Block I, Müller C, Langkjær N, Høilund-Carlsen PF, Olsen BB, Mollenhauer J. Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411. PLoS One 2017;12:e0178286. [PMID: 28542563 DOI: 10.1371/journal.pone.0178286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Ezzatifar F, Rafiei A, Jeddi-tehrani M. Nucleolin; A tumor associated antigen as a potential lung cancer biomarker. Pathology - Research and Practice 2022;240:154160. [DOI: 10.1016/j.prp.2022.154160] [Reference Citation Analysis]
2 Saravanakumar K, Sathiyaseelan A, Mariadoss AVA, Hu X, Venkatachalam K, Wang M. Nucleolin targeted delivery of aptamer tagged Trichoderma derived crude protein coated gold nanoparticles for improved cytotoxicity in cancer cells. Process Biochemistry 2021;102:325-32. [DOI: 10.1016/j.procbio.2021.01.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
3 Yin J, Chen S, Song Y, Wang H. Fluorescent imaging of cytoplasmic nucleolin in live cells by a functionalized-engineered aptamer. Chem Commun (Camb) 2020;56:14171-4. [PMID: 33156312 DOI: 10.1039/d0cc06347a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Yang B, Wang Y, Chen Z, Feng YM, Shi LL. Effects of Apatinib on the "Stemness" of Non-Small-Cell Lung Cancer Cells In Vivo and Its Related Mechanisms. Can Respir J 2020;2020:2479369. [PMID: 32849930 DOI: 10.1155/2020/2479369] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Wieleba I, Wojas-Krawczyk K, Krawczyk P. Aptamers in Non-Small Cell Lung Cancer Treatment. Molecules 2020;25:E3138. [PMID: 32659994 DOI: 10.3390/molecules25143138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 He XY, Ren XH, Peng Y, Zhang JP, Ai SL, Liu BY, Xu C, Cheng SX. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression. Adv Mater 2020;32:e2000208. [PMID: 32147886 DOI: 10.1002/adma.202000208] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 28.0] [Reference Citation Analysis]
7 Fu X, Peng F, Lee J, Yang Q, Zhang F, Xiong M, Kong G, Meng HM, Ke G, Zhang XB. Aptamer-Functionalized DNA Nanostructures for Biological Applications. Top Curr Chem (Cham) 2020;378:21. [PMID: 32030541 DOI: 10.1007/s41061-020-0283-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
8 Saravanakumar K, Hu X, Shanmugam S, Chelliah R, Sekar P, Oh DH, Vijayakumar S, Kathiresan K, Wang MH. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles. Arch Biochem Biophys 2019;671:143-51. [PMID: 31283911 DOI: 10.1016/j.abb.2019.07.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
9 Li P, Xing W, Xu J, Yuan D, Liang G, Liu B, Ma H. microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther 2019;10:144. [PMID: 31113460 DOI: 10.1186/s13287-019-1235-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
10 Abnous K, Danesh NM, Ramezani M, Charbgoo F, Bahreyni A, Taghdisi SM. Targeted delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of AS1411 and FOXM1 aptamers. Expert Opin Drug Deliv 2018;15:1045-52. [PMID: 30269603 DOI: 10.1080/17425247.2018.1530656] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
11 Kuan SL, Fischer S, Hafner S, Wang T, Syrovets T, Liu W, Tokura Y, Ng DYW, Riegger A, Förtsch C, Jäger D, Barth TFE, Simmet T, Barth H, Weil T. Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins. Adv Sci (Weinh) 2018;5:1701036. [PMID: 30128225 DOI: 10.1002/advs.201701036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
12 Ugrinova I, Petrova M, Chalabi-dchar M, Bouvet P. Multifaceted Nucleolin Protein and Its Molecular Partners in Oncogenesis. Advances in Protein Chemistry and Structural Biology 2018. [DOI: 10.1016/bs.apcsb.2017.08.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
13 Yang S, Ren Z, Chen M, Wang Y, You B, Chen W, Qu C, Liu Y, Zhang X. Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual pH/Redox Sensitivity Designed To Enhance Tumor Therapy through the Codelivery of Doxorubicin/TLR4 siRNA and Suppression of Invasion. Mol Pharm 2018;15:314-25. [PMID: 29250957 DOI: 10.1021/acs.molpharmaceut.7b01093] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
14 Wu H, Wang M, Dai B, Zhang Y, Yang Y, Li Q, Duan M, Zhang X, Wang X, Li A, Zhang L. Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics. Drug Deliv 2017;24:1216-29. [PMID: 28845698 DOI: 10.1080/10717544.2017.1367976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
15 de Franciscis V. Challenging cancer targets for aptamer delivery. Biochimie 2018;145:45-52. [PMID: 28962871 DOI: 10.1016/j.biochi.2017.09.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
16 Qi Y, Liu X, Li J, Yao H, Yuan S. Fluorine-18 labeled amino acids for tumor PET/CT imaging. Oncotarget 2017;8:60581-8. [PMID: 28947996 DOI: 10.18632/oncotarget.19943] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
17 Jia W, Yao Z, Zhao J, Guan Q, Gao L. New perspectives of physiological and pathological functions of nucleolin (NCL). Life Sci 2017;186:1-10. [PMID: 28751161 DOI: 10.1016/j.lfs.2017.07.025] [Cited by in Crossref: 105] [Cited by in F6Publishing: 116] [Article Influence: 21.0] [Reference Citation Analysis]